A new product to reduce obesity in humans

Developed by: Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca


Low plasma levels of the identified molecule are found in metabolic disorders and predict an increased risk of developing type 2 diabetes and cardiovascular disease. Beyond this biomarker role, it has been demonstrated that it plays a role in the development and progression of these diseases by reducing the lipid content in human hepatocytes and adipocytes due to its role as lipolytic agent and inhibitor of the lipogenesis. So, this can be a good approach for the treatment of obesity and related illnesses.

Stage of development: TRL 3, Validated in the laboratory.

IP: Patent application in national phases in EP and US.

Health technology: